Penetrate New Markets

• Approximately 75% of the world’s hemophilia population not adequately treated

• Lead market penetration with hemophilia in less developed markets

• Leverage Baxter position and capabilities worldwide

• Leverage hemophilia portfolio to introduce other BioPharmaceuticals, Vaccines and BioSurgery products and services

Significant Sales Opportunity Outside of United States and Europe

Concentrated Factor VIII

Lead With Hemophilia

< 10%

> 90%

Previous slide

Next slide

Back to first slide

View graphic version